Xenon Pharmaceuticals Inc
Suletud
SektorTervishoid
54.74 1.2
Ülevaade
Aktsiahinna muutus
24h
Min
53.89
Max
55.53
Sissetulek | 3M -102M |
|---|---|
Aktsiakasum | -1.17 |
Töötajad | 358 |
EBITDA | -7.6M -112M |
Soovitused | Tugev "osta" hinnang |
|---|---|
12 kuu keskmine prognoos | +40.87% upside |
Järgmine tulemuste avaldamine | 10. aug 2026 |
|---|
Turukapital | -482M 5.1B |
|---|---|
Eelmine avamishind | 53.54 |
Eelmine sulgemishind | 54.74 |
Uudiste sentiment
By Acuity
50%
50%
128 / 342 Pingereas Healthcare
Xenon Pharmaceuticals Inc Graafik
Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.
Ettevõttest Xenon Pharmaceuticals Inc
Xenon Pharmaceuticals Inc., a neuroscience-focused biopharmaceutical company, engages in the development of therapeutics to treat patients with neurological disorders in Canada. Its clinical development pipeline includes XEN1101, a novel and potent Kv7 potassium channel opener, which is in Phase 3 clinical trials for the treatment of epilepsy and other neurological disorders. The company has a license and collaboration agreement with the Neurocrine Biosciences, Inc. for the development of NBI-921352, a selective Nav1.6 sodium channel inhibitor that is in Phase 2 clinical trials for the treatment of SCN8A developmental and epileptic encephalopathy, and other indications, including adult focal epilepsy. Xenon Pharmaceuticals Inc. was incorporated in 1996 and is headquartered in Burnaby, Canada.
